<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94035">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01833455</url>
  </required_header>
  <id_info>
    <org_study_id>UW-PVC-2012-0510</org_study_id>
    <nct_id>NCT01833455</nct_id>
  </id_info>
  <brief_title>Premature Ventricular Contractions (PVCs) and Blood Pressure Control</brief_title>
  <official_title>The Effects of PVC Suppression on Blood Pressure Control in Patients With Frequent PVCs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if reduction in premature ventricular contraction
      (PVC) burden results in a decrease in blood pressure, sympathetic outflow, plasma
      catecholamines and an improvement in baroreflex gain. Flecainide will be used for PVC
      suppression in a randomized, double-blinded, crossover fashion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change in Blood Pressure</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Sympathetic Nerve Activity</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Baroreflex Gain</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Ventricular Premature Complexes</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>PVC Suppression then Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then PVC Suppression</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PVC Suppression using Flecainide</intervention_name>
    <description>Flecainide will be administered to result in a reduction in PVC burden.</description>
    <arm_group_label>PVC Suppression then Placebo</arm_group_label>
    <arm_group_label>Placebo then PVC Suppression</arm_group_label>
    <other_name>Tambocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No PVC Suppression using Placebo</intervention_name>
    <description>Placebo (sugar pills) will be given to result in no alteration in PVC burden.</description>
    <arm_group_label>PVC Suppression then Placebo</arm_group_label>
    <arm_group_label>Placebo then PVC Suppression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Frequent symptomatic premature ventricular contractions (PVCs) (&gt;10% of total QRSs on
             a 24-hour Holter)

          -  Willingness to participate in research

        Exclusion Criteria:

          -  Age &gt; 65 years old

          -  Pacemaker implantation

          -  Implantable cardioverter defibrillator implantation requiring pacing

          -  Sick sinus syndrome

          -  Atrio-ventricular (AV) block

          -  Left ventricular dysfunction defined as left ventricular ejection fraction &lt; 50%

          -  History of myocardial infarction or coronary artery disease

          -  Severe left ventricular hypertrophy (wall thickness &gt; 1.5 cm by echocardiography
             performed within 3 months from enrollment)

          -  Severe liver dysfunction

          -  Creatinine clearance of 35 mL/min/1.73 square meters or less

          -  Pregnancy

          -  Known hypersensitivity to the drug

          -  QRS duration &gt; 120 ms

          -  Recent change in blood pressure medication within 30 days of enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed H Hamdan, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joy Amundson, MSN</last_name>
    <phone>608-262-0625</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen L Wasmund, PhD</last_name>
      <phone>608-263-8005</phone>
      <email>swasmund@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Mohamed Hamdan, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 12, 2013</lastchanged_date>
  <firstreceived_date>April 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Flecainide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
